EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

The Committee for Medicinal Products for Human Use (CHMP) has recommended that the subcutaneous (SC) formulation be approved ...

The European Commission (EC) has granted marketing authorisation of amivantamab in the following indications: In combination in with carboplatin and pemetrexed, for the treatment of adult patients ...

The CHMP recommends approval for JNJ's subcutaneous formulation of Rybrevant in NSCLC and AstraZeneca's Imfinzi in limited-stage small-cell lung cancer.

In this video, Xiuning Le, MD, PhD, discusses how the definition of EGFR-mutated lung cancer has expanded in recent years.

EU regulators have issued a positive opinion for the extension of the market authorization for subcutaneous formulation of ...

The European Commission approved Tagrisso for the treatment of adults with locally advanced, unresectable NSCLC whose tumors have EGFR exon 19 deletions or exon 21 substitution (L858R) mutations ...

A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review.

A separate NDA for the first-line treatment in adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations is currently under NMPA review. Lung ...